1.1Renal glucose transport inhibition
An oral small molecule reduces glucose and sodium reabsorption in the proximal renal tubule. This treatment reduces the rate of worsening heart failure events in patients with preserved ejection fraction.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
An oral small molecule reduces glucose and sodium reabsorption in the proximal renal tubule. This treatment reduces the rate of worsening heart failure events in patients with preserved ejection fraction.
An oral small molecule blocks aldosterone-dependent activation of the mineralocorticoid receptor. In symptomatic heart failure with a left ventricular ejection fraction of at least 40 percent, this treatment reduces worsening heart failure events.
A weekly subcutaneous peptide activates receptors for glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. The regimen reduces body weight and improves heart failure symptom scores in this population.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A synthetic small interfering RNA duplex replaces the small-molecule or peptide inhibitor in an injectable formulation. The duplex contains a guide strand complementary to a region of human JUN messenger RNA shared by the transcripts expressed in the target cells. An ionizable lipid nanoparticle carries the duplex, and cells that take it up and release it into the cytosol use the guide strand to direct cleavage of JUN messenger RNA.
A stable patient completes scheduled walking or stationary cycling sessions at an intensity set using a baseline exercise test. Repeated training improves peak oxygen uptake and functional capacity in patients with preserved ejection fraction.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
This UV-induced inhibition of the synthesis of collagen can be prevented by the topical application of a retinoid or c-JUN inhibitor to the skin prior to exposure to UV radiation.A · US 7,141,238 B2 · abstract
A method for treating diastolic heart failure (heart failure with preserved ejection fraction (HFpEF)) in a subject in need thereof is provided including administering a therapeutically effective amount of a galectin-3 inhibitor to the subject.B · US 2021/0330694 A1 · abstract
An empty cell means only that no passage was reproduced there.
More particularly, the invention relates to compositions and methods for this use by topical application to reduce if not eliminate the inhibition of collagen synthesis in human skin after incidental and/or direct exposure to UV radiation as would occur daily, and as would occur after recreational exposure to UV radiation during a planned, extended period in the sun.A · US 7,141,238 B2 · ¶ 3
Photoaging is a term presently used to describe the changes in appearance and/or function of human skin as a result of repeated exposure to sunlight, and especially in reference to wrinkles and other changes in the appearance of the skin thought to be related to exposure to the sun.A · US 7,141,238 B2 · ¶ 7
Embodiments relate to treating diastolic heart failure by inhibiting galectin-3.B · US 2021/0330694 A1 · ¶ 2
Identifying effective therapies to treat diastolic HF is a major unmet need in the United States and worldwide.B · US 2021/0330694 A1 · ¶ 4
patent.fyi, US 2026/0355164 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355164/, SHA-256 8131fb9af0ca9b4947a797629fd16398d2161b75435c7268153d4b8618de2202